Profile of Dysphagia in Myotonic Dystrophy Type 1 (DM1)
NCT ID: NCT05865483
Last Updated: 2025-08-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
177 participants
OBSERVATIONAL
2023-07-03
2024-08-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* whether the size and structure of the muscles involved in swallowing differ to those without the disease
* how the size and structure of muscles may associate with swallowing function and swallowing symptoms in this group.
Participants will undergo a range of tests including:
* Ultrasound (US) assessment of the muscles involved in swallowing
* An x-ray swallowing study (known as videofluoroscopy)
* Assessment of swallowing symptoms, including questionnaires
* Assessments of mobility, activity and breathing
* Assessments of quality of life and wellbeing
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Electrical Muscle Stimulation to Aid Swallowing in Dysphagia
NCT00001936
Breathlessness Assessment in Adult Patients With Myotonic Dystrophy Type 1
NCT04835298
Muscle Tissue Bank for Muscular Dystrophy
NCT01950897
Study of Muscle Wasting and Altered Metabolism in Patients With Myotonic Dystrophy
NCT00004769
Treatment of Dysphagia in Oculopharyngeal Muscular Dystrophy by Autologous Transplantation of Myoblasts
NCT00773227
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A better understanding of dysphagia in DM1 will improve our assessment and treatment and reduce its life-changing consequences. This research aims to define the dysphagia profile of people with DM1 (pwDM1) across the domains of structure, function, experience, and wellbeing by:
1. Investigating the size and structure of muscles involved in swallowing in patients with and without DM1.
2. Exploring how muscle size and structure are associated with i) swallowing function and ii) symptoms
3. Exploring how swallowing function is associated with i) symptoms, ii) patient and caregiver wellbeing and iii) other aspects of DM1 such as walking and breathing.
People aged 18+ with a confirmed diagnosis of DM1 will be invited to take part. Approximately 90 pwDM1 will be recruited. They will undergo a battery of tests including:
* Ultrasound (US) assessment of the muscles involved in swallowing
* An x-ray swallowing study (known as videofluoroscopy)
* Assessment of swallowing symptoms, including questionnaires
* Assessments of mobility, activity and breathing
* Assessments of quality of life and wellbeing
A sub-group of 20 pwDM1 will also undergo magnetic resonance imaging (MRI) of the muscles involved in swallowing to examine in detail the changes in seen on ultrasound. Approximately 60 people without DM1 will act as a control group for the US assessments. Primary caregivers of those with DM1 will be invited to complete a wellbeing questionnaire.
Data will be analysed using statistical methods and findings will be used to develop clinical practice recommendations for the assessment and treatment of dysphagia in DM1.
This study is part of an NIHR-funded clinical doctoral research fellowship (CDRF) and will take place at The National Hospital for Neurology and Neurosurgery (NHNN) in London. The maximum timescale for the study from opening recruitment to data collection of the final participant is 18 months (approx. 1st April 2023 - 30th September 2024).
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Participant group: mild disease
Muscle impairment rating score (MIRS) (Mathieu et al., 2001) 1-2 (n=30)
No interventions assigned to this group
Participant group: moderate disease
Muscle impairment rating score (MIRS) (Mathieu et al., 2001) 3 (n=30)
No interventions assigned to this group
Participant group: severe disease
Muscle impairment rating score (MIRS) (Mathieu et al., 2001) 4-5 (n=30)
No interventions assigned to this group
Control group
No disease (n=60) age and sex-matched
No interventions assigned to this group
Caregiver group
Spends at least one mealtime daily assisting with a person with DM1 already enrolled in the study. Expect ratio of 1:2 caregiver:participant (approx n=45)
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* genetically confirmed of DM1
* able to eat \& drink at least five sips of liquid by mouth at one time.
Exclusion:
* any condition or treatment other than DM1 that potentially influences swallowing muscle composition or function (e.g., a history of stroke or throat cancer).
* any patients who are pregnant
* patients with congenital or childhood DM1
* patients who are not able to eat or drink anything by mouth.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute for Health Research, United Kingdom
OTHER_GOV
Myotonic Dystrophy Support Group, United Kingdom
UNKNOWN
The National Brain Appeal, The National Hospital for Neurology and Neurosurgery
UNKNOWN
University College, London
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Stuart Taylor, PhD
Role: PRINCIPAL_INVESTIGATOR
University College London & University College London Hospitals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The National Hospital for Neurology & Neurosurgery, University College London Hospitals
London, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Mathieu J, Boivin H, Meunier D, Gaudreault M, Begin P. Assessment of a disease-specific muscular impairment rating scale in myotonic dystrophy. Neurology. 2001 Feb 13;56(3):336-40. doi: 10.1212/wnl.56.3.336.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
153848
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.